Cargando…

Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18

Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paiardini, Alessandro, Bamert, Rebecca S., Kannan-Sivaraman, Komagal, Drinkwater, Nyssa, Mistry, Shailesh N., Scammells, Peter J., McGowan, Sheena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336144/ https://www.ncbi.nlm.nih.gov/pubmed/25700165 http://dx.doi.org/10.1371/journal.pone.0115859

Ejemplares similares

Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening
por: Ruggeri, Chiara, et al.
Publicado: (2015)

A metal ion–dependent conformational switch modulates activity of the Plasmodium M17 aminopeptidase
por: Webb, Chaille T., et al.
Publicado: (2022)

Mapping the substrate specificity of the Plasmodium M1 and M17 aminopeptidases
por: Malcolm, Tess R., et al.
Publicado: (2021)

Fingerprinting the Substrate Specificity of M1 and M17 Aminopeptidases of Human Malaria, Plasmodium falciparum
por: Poreba, Marcin, et al.
Publicado: (2012)

Sitagliptin does not inhibit the M1 alanyl aminopeptidase from Plasmodium falciparum
por: McGowan, Sheena
Publicado: (2013)

Active site metals mediate an oligomeric equilibrium in Plasmodium M17 aminopeptidases
por: Malcolm, Tess R., et al.
Publicado: (2020)

The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
por: Looker, Oliver, et al.
Publicado: (2022)

Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway
por: Edgar, Rebecca CS, et al.
Publicado: (2022)

Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box
por: Jung, Eric H., et al.
Publicado: (2018)

The Plasmodium falciparum Malaria M1 Alanyl Aminopeptidase (PfA-M1): Insights of Catalytic Mechanism and Function from MD Simulations
por: Jones, Peter M., et al.
Publicado: (2011)

Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules
por: Subramanian, Gowtham, et al.
Publicado: (2018)

Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites
por: Nugraha, Arifin Budiman, et al.
Publicado: (2019)

Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP)
por: Mathew, Rency, et al.
Publicado: (2021)

Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
por: Nyagwange, James, et al.
Publicado: (2019)

Modeling of human M1 aminopeptidases for in silico screening of potential Plasmodium falciparum alanine aminopeptidase (PfA-M1) specific inhibitors
por: Sahi, Shakti, et al.
Publicado: (2014)

IgM in human immunity to Plasmodium falciparum malaria
por: Boyle, M. J., et al.
Publicado: (2019)

Erratum for Subramanian et al., “Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules”
por: Subramanian, Gowtham, et al.
Publicado: (2019)

Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
por: Tadele, Markos, et al.
Publicado: (2020)

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box
por: Jumani, R. S., et al.
Publicado: (2018)

Identification of an Atg8-Atg3 Protein–Protein Interaction Inhibitor from the Medicines for Malaria Venture Malaria Box Active in Blood and Liver Stage Plasmodium falciparum Parasites
por: Hain, Adelaide U.P., et al.
Publicado: (2014)

Structural basis for epitope masking and strain specificity of a conserved epitope in an intrinsically disordered malaria vaccine candidate
por: Morales, Rodrigo A. V., et al.
Publicado: (2015)

Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
por: Pasche, Valérian, et al.
Publicado: (2018)

Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box
por: Bhandari, Vasundhra, et al.
Publicado: (2018)

PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion
por: Barnes, Claudia B. G., et al.
Publicado: (2022)

The M18 aspartyl aminopeptidase of Plasmodium falciparum binds to human erythrocyte spectrin in vitro
por: Lauterbach, Sonja B, et al.
Publicado: (2008)

The mRNA-bound proteome of the human malaria parasite Plasmodium falciparum
por: Bunnik, Evelien M., et al.
Publicado: (2016)

In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica
por: Tadele, Markos, et al.
Publicado: (2021)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

Plasmodium falciparum dipeptidyl aminopeptidase 3 activity is important for efficient erythrocyte invasion by the malaria parasite
por: Lehmann, Christine, et al.
Publicado: (2018)

Plasmodium falciparum–specific IgM B cells dominate in children, expand with malaria, and produce functional IgM
por: Hopp, Christine S., et al.
Publicado: (2021)

Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
por: Wall, Gina, et al.
Publicado: (2019)

Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi
por: Almeida-Paes, Rodrigo, et al.
Publicado: (2021)

M1 macrophage features in severe Plasmodium falciparum malaria patients with pulmonary oedema
por: Klinkhamhom, Aekkarin, et al.
Publicado: (2020)

IRAP Inhibitors: M1-Aminopeptidase Family Inspiration
por: Barlow, Nicholas, et al.
Publicado: (2020)

Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
por: Khraiwesh, Mozna, et al.
Publicado: (2016)

Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
por: Duffy, Sandra, et al.
Publicado: (2017)

M. T. Malaria Simulating Acute Abdomen
por: Rao, T. M.
Publicado: (1948)

Plasmodium falciparum PfA-M1 aminopeptidase is trafficked via the parasitophorous vacuole and marginally delivered to the food vacuole
por: Azimzadeh, Omid, et al.
Publicado: (2010)

Exploration of Sitagliptin as a potential inhibitor for the M1 Alanine aminopeptidase enzyme in Plasmodium falciparum using computational docking
por: Krishnamoorthy, Mohana, et al.
Publicado: (2013)

Overexpression of Plasmodium falciparum M1 Aminopeptidase Promotes an Increase in Intracellular Proteolysis and Modifies the Asexual Erythrocytic Cycle Development
por: Hoff, Carolina C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vg51c0s0t1gv2jh538j33t9ble